Rheumatoid arthritis (RA) is a chronic autoimmune disease in which the immune system mistakenly attacks the lining of the joints, causing pain, swelling, and stiffness that typically affects both sides of the body. About 4.1% of U.S. adults have been diagnosed with RA, making it the second most common form of arthritis after osteoarthritis. Unlike osteoarthritis, which results from wear and tear on cartilage, RA is driven by inflammation that can damage joints and affect organs throughout the body.
How RA Differs From Other Arthritis
The defining feature of RA is that it starts in the synovium, the thin membrane lining each joint. In a healthy joint, this membrane produces a small amount of fluid that keeps things lubricated. In RA, immune cells flood into the synovium, causing it to thicken and swell. The membrane grows extra layers of tissue, new blood vessels form to feed the inflamed area, and the whole process releases chemicals that gradually eat away at cartilage and bone.
One of the key immune signals driving this damage is tumor necrosis factor, a protein that ramps up inflammation. The discovery of its role in RA led to an entire class of treatments that block it, which transformed how the disease is managed. But the inflammation doesn’t stay neatly contained in the joints. Roughly 40% of people with RA develop problems outside the joints, including effects on the skin, eyes, lungs, heart, blood vessels, and nervous system.
Who Gets RA
RA can strike at any age, but prevalence climbs steadily with time. Among adults aged 20 to 44, about 1.9% have RA. That number jumps to around 5.9% for those aged 45 to 54 and reaches 7.5% for adults 75 and older. Historically, RA has been considered more common in women, but recent CDC data found no statistically significant difference in prevalence between men and women across the general U.S. adult population.
Symptoms and Early Warning Signs
RA often announces itself subtly. Weeks or even months before joint problems appear, many people notice persistent fatigue, a general feeling of being unwell, and sometimes depression. These vague symptoms are easy to dismiss, but they can be early signals of the immune activity building underneath.
When joint symptoms arrive, stiffness is usually the first thing people notice, often accompanied by pain when moving and tenderness to the touch. Morning stiffness is a hallmark: it typically lasts more than an hour and often persists for several hours, which distinguishes RA from osteoarthritis (where stiffness tends to ease within 30 minutes). The disease may start in just a few joints, but it almost always becomes polyarticular over time, eventually involving five or more joints.
Symmetrical swelling is characteristic. If the knuckles on your left hand are swollen, the same knuckles on your right hand often are too. That said, symmetry isn’t always present early on, so its absence doesn’t rule out RA. The small joints of the hands, wrists, and feet are the most commonly affected, though larger joints like the knees, shoulders, elbows, and ankles can be involved as well.
How RA Is Diagnosed
There’s no single test that confirms RA. Doctors use a combination of physical examination, blood work, and imaging to piece together a diagnosis. The most widely used framework is a scoring system developed jointly by the American College of Rheumatology and the European League Against Rheumatism, which assigns points across four categories: the number and type of joints involved, blood test results, markers of inflammation, and how long symptoms have lasted. A score of 6 out of 10 or higher qualifies as definite RA.
Two blood tests play a central role. Rheumatoid factor (RF) is an antibody found in most people with RA, with a sensitivity of about 91%, meaning it catches the vast majority of cases. The tradeoff is that RF can also be positive in people who don’t have RA, giving it a specificity of around 74%. Anti-CCP antibodies are more precise: they have a similar sensitivity (88%) but a much higher specificity (90.4%), meaning a positive result is more likely to reflect true RA. When both tests are used together, diagnostic accuracy improves further. Doctors also check inflammatory markers like C-reactive protein and erythrocyte sedimentation rate, which indicate how much active inflammation is present.
If symptoms have been present for six weeks or longer and enough points accumulate across these categories, a formal diagnosis is made. People who fall just short of the threshold may still develop RA later and can be reclassified as the disease evolves.
Joint Damage and Why Early Treatment Matters
RA damages joints in 80% to 85% of patients, and the bulk of that damage happens within the first two years. This is why rheumatologists push for early, aggressive treatment. The goal is to intercept the disease before it causes irreversible erosion of bone and cartilage. Current guidelines follow a “treat-to-target” strategy: disease activity should drop by at least 50% within three months, and the ultimate target, ideally remission or at minimum low disease activity, should be reached within six months. If those benchmarks aren’t met, treatment is adjusted.
Treatment Options
The first medication most people with RA receive is methotrexate, a traditional disease-modifying drug (DMARD) that broadly dials down immune system activity. It’s typically started alongside a short course of corticosteroids to bring inflammation under control quickly. Methotrexate is taken as a pill and remains the backbone of RA treatment because it’s effective, well-studied, and causes fewer side effects than stronger alternatives.
If methotrexate alone isn’t enough after three to six months, a biologic DMARD is usually added. Biologics are lab-engineered proteins that target specific parts of the immune system rather than suppressing it broadly. The main categories include drugs that block tumor necrosis factor, drugs that block interleukins (another group of inflammatory signals), and drugs that target specific immune cells called T-cells or B-cells. Biologics are more powerful than traditional DMARDs but carry a higher risk of side effects, particularly infections.
A newer class called JAK inhibitors works similarly to biologics by targeting a specific signaling pathway inside immune cells, but they come in pill form rather than requiring injections. They’re generally considered after biologics, in part because of concerns about cardiovascular events and blood clots in certain patient populations.
Effects Beyond the Joints
Because RA is a systemic inflammatory disease, it can reach well beyond the joints. About 40% of patients experience problems in other parts of the body. The most common include rheumatoid nodules (firm lumps under the skin near affected joints), dry eyes and dry mouth from inflammation of moisture-producing glands, and lung involvement ranging from inflammation of the lung lining to scarring of lung tissue. Cardiovascular risk is also elevated: the same inflammatory chemicals that damage joints can accelerate plaque buildup in blood vessels. There is some evidence that certain complications like nodules and blood vessel inflammation have become less frequent since the mid-1990s, likely due to more effective treatments.
Exercise and Lifestyle
Exercise is one of the most consistently supported non-drug strategies for managing RA. Programs lasting 12 weeks or longer have been shown to reduce disease activity, and the European League Against Rheumatism formally recommends physical exercise alongside medication. The benefits go beyond joint health: studies show improvements in pain, cardiovascular fitness, fatigue, balance, and overall quality of life. A combination of moderate aerobic exercise and resistance training, done about three times a week for 30 to 60 minutes, is the most studied approach. Importantly, these gains aren’t temporary. Follow-up assessments at 12 months after structured exercise programs show that improvements in endurance and functional ability tend to persist.
One study found that even a simple home-based routine of strengthening and range-of-motion exercises, performed five days a week for just four weeks, improved physical function and quality of life, with benefits still detectable a full year later. The key is consistency rather than intensity. Low- to moderate-impact activities reduce oxidative stress and improve the body’s antioxidant defenses, addressing some of the underlying biological processes that drive RA inflammation.